Brookhaven Science Associates U.S. Department of Energy 1 Brookhaven National Laboratory Protocol Compliance Monitoring Darcy Mallon May 7, 2009.

Slides:



Advertisements
Similar presentations
The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.
Advertisements

Managing Compliance Related to Human Subjects Research Review Joseph Sherwin, Ph.D. Office of Regulatory Affairs University of Pennsylvania Fourth Annual.
What FDA Looks for When Inspecting IRBs and Sponsors Marian J. Serge Nurse Consultant Division of Bioresearch Monitoring Office of Compliance Center for.
Tips to a Successful Monitoring Visit
The HRPP FYI Process and the UPIRSO/SAE Review Sheet An IRB Infoshort February 2014.
Susan Burner Bankowski, M.S., J.D. Chair, OHSU IRB
Chicken Soup for the Busy Coordinator
How To Impact Your Research: An Overview of Research Support Services Quincy J. Byrdsong, Terri Hagan, and Alice Owens-Gatlin Research Services Consultants.
What is a Data and Safety Monitoring Plan and how do I get one? Presented by Office of Human Research Protection.
Audit Ebru Mutlu-Omega CRO. General Purpose to help quality (to maintain quality at present) to assure quality (make sure that quality in future is maintained)
UTHSC IRB Donna Hollaway, RN, CCRC 11/30/2011 Authority to Audit 45 CFR (e) An IRB shall conduct continuing review of research covered by this.
IRB Determinations 1. AAHRPP Site Visit Results Site visitors observed a real commitment to human subject protections Investigator and research staff.
IRB-Investigator/ Research Coordinator Mtg. “CUMC’s New Progressive Policy For Adverse Event Reporting” April 13, 2004 George Gasparis Andrew Wit, Ph.D.
Columbia University IRB IRB 101 September 21, 2005 George Gasparis, Executive Director, CU IRB Asst. V.P. and Sr. Asst. Dean for Research Ethics.
CUMC IRB Investigator Meeting Human Subjects Research Non-Compliance September 15, 2005.
Human Research Protection Program Training: Post-Approval Event Reporting March 26, 2008 Lisa Voss, MPH, CIP Assistant Director, QIU Human Research Protection.
Clinical Pharmacy’s Role in Research Trials Sheree Miller Pharm.D. Investigational Drug Service University of Washington Medical Center.
Unlocking the Mystery of General Information Reporting Research Compliance Administration Training Presentation Wednesday, June 6, 2007 Presenter:Heather.
Institutional Review Board (IRB) Human Subject Research Office (HSRO) University of Miami and Affiliated Institutions.
Internal Auditing in Research: The QA Process Research Education Series February 14, 2011 Sarah Dutkevitch, RN, OCN, Clinical Research Nurse Specialist.
PRESENTING A PROTOCOL AN IRB INFOSHORT FEBRUARY 2013.
Continuing Review VA Requirements Kevin L. Nellis, M.S., M.T. (A.S.C.P.) Program Analyst Program for Research Integrity Development and Education (PRIDE)
Who’s the Boss? Faculty Advisor or Principal Investigator Supervision versus Student Investigator or Study Coordinator Responsibilities Gwenn Snow, MS,
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
International Research & Research Involving Children K. Lynn Cates, MD Assistant Chief Research & Development Officer Office of Research & Development.
Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst.
Using Technology to Strengthen Human Subject Protections Patricia Scannell Director, IRB Washington University School of Medicine.
ORO Reviews: Frequent Findings Related to IRBs Bob Brooks Associate Director Research Compliance Education and Policy VHA Office of Research Oversight.
THE ROLE OF DSMB’s in CLINICAL RESEARCH Data and Safety Monitoring Monitoring.
Monitoring, Audits, and Inspection Oh my! Rachel Sheppard Regulatory Director, OCRSS.
Unanticipated Problems Potentially Involving Risks to Subjects or Others Research Protections Office Serving UVM and FAHC Updated April 2012.
Common Audit Findings UTHSC Institutional Review Board (IRB)
RESCUE: ACRIN 4701 Protocol Development & Regulatory Compliance (PDRC) Josephine Schloesser, ACRIN Monitor Chris Steward, ACRIN QC Auditor.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
Monitoring IRB Monitoring of Clinical Trials. Types of Monitoring Internally Internally Externally Externally.
H I P A A T R A I N I N G Self Directed Module 7 Research Disclosures For Data Custodians START Click to begin…
THE ROLE OF DSMB’s in CLINICAL RESEARCH Data and Safety Monitoring Monitoring.
The Research Subject Advocate (RSA). Pictured, left to right: Andrea Saltzman, RN; Enrico Cagliero, MD; Debi Dunkless.
Overview of Gene Therapy Surveillance Inspections Joseph P Salewski, Chief Bioresearch Monitoring Branch CBER.
Yadvindera (Bobby) Bains MD Director of Radiation Oncology, Laredo Medical Center Adjunct Associate Professor, Dept of Radiation Oncology, University of.
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Site Monitoring Shirley Frederiksen Donna Harsh.
Investigational Devices and Humanitarian Use Devices June 2007.
Enrollment and Monitoring Procedures for NCI Supported Clinical Trials Barry Anderson, MD, PhD Cancer Therapy Evaluation Program National Cancer Institute.
How to Start An Industry Sponsored Clinical Trial
RIHES-II: H ANDLING A UDITS AND I NSPECTIONS E FFECTIVE D ATE 25 D ECEMBER 2006 V ERSION : 3.0 บุญเหลือ พรึงลำภู 15 มกราคม 2557.
Office of Human Research Protection Georgia Health Sciences University.
Conducting Research at Lincoln IRB/HRPP Policies, Procedures & Good Clinical Practices B Kanna MD, MPH, FACP Associate Program Director of Internal Medicine.
CONDUCTING COMPLIANCE ASSESSMENTS Allen Ditch Director Corporate Quality Bristol Myers Squibb Medical Research Summit March 6, 2003.
THE INSTITUTIONAL REVIEW BOARD. WHAT IS AN IRB? An IRB is committee set up by an institution to review, approve, and regulate research conducted under.
IRB BASICS BETTY WILSON, MS, CIP. CONCEPTS SUBMISSION APPROVAL RECRUITING WORKING WITH PRINCIPAL INVESTIGATOR (PI) /SPONSOR POLICIES DEVIATIONS RECORD.
Session 2 IRB Training  What is the Principal Investigator’s role in Human Subject Research?  What is the role of the Investigator’s staff in Human Subject.
Slide 1 Standard Operating Procedures. Slide 2 Goal To review the standard operating procedures Creating the informed consent document Obtaining informed.
Good Clinical Practice (GCP) and Monitoring Practices
Lisa Hoebelheinrich, JD, CHRC Associate Vice Chancellor, Compliance
Introduction Review and proper registration of Human Gene Transfer protocols is very complex. A protocol goes through rigorous review by multiple Committees.
Dartmouth Human Research Protection Program (HRPP) Data Safety Monitoring and Reporting requirements Brown Bag Series: Noon / First Tuesday of the Month.
The Role and Responsibilities of the Clinical Research Coordinator
Responsibilities of Sponsor, Investigator and Monitor
FDA’s IDE Decisions and Communications
What is a Data and Safety Monitoring Plan and how do I get one?
Reportable Events & Other IRB Updates February 2017
Reasons for Auditing There are many reasons for auditing. Some examples of these reasons might be: Requested by the IRB Committee Requested by an IRB.
THE ROLE OF DSMB’s in CLINICAL RESEARCH
Elements of an Organized Regulatory Binder
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
Monitoring, Auditing and Compliance
Quality Assurance in Clinical Trials
Protocol Approval Criteria
Presentation transcript:

Brookhaven Science Associates U.S. Department of Energy 1 Brookhaven National Laboratory Protocol Compliance Monitoring Darcy Mallon May 7, 2009

Brookhaven Science Associates U.S. Department of Energy 2 OUTLINE n Role of Research Subject Advocate (RSA) n Protocol Compliance Monitoring Plan

Brookhaven Science Associates U.S. Department of Energy 3 RESEARCH SUBJECT ADVOCATE n BNL is funded in part by a General Clinical Research Center (GCRC) grant through State University of Stony Brook at New York (SBU) n GCRC funding comes from the National Center for Research Resources (NCRR) n GCRC funded institutions are required to have a Research Subject Advocate (RSA)

Brookhaven Science Associates U.S. Department of Energy 4 RESEARCH SUBJECT ADVOCATE n The RSA is responsible for monitoring human subjects research activities and reporting corrective actions if deficiencies are found. n The RSA reviews active protocols and prepares reports that are sent to the Brookhaven National Laboratory (BNL) Clinical Research Quality Assurance Committee (CRQAC) and the SBU Institutional Review Board, the Committee on Research Involving Human Subjects (CORIHS) n All protocols are required to have a Data Safety Monitoring Plan (DSMP). Multicenter, high-risk and/or Phase III protocols are required to have a Data Safety Monitoring Board (DSMB).

Brookhaven Science Associates U.S. Department of Energy 5 PROTOCOL COMPLIANCE MONITORING n The RSA randomly selects a BNL protocol for review. n The scope of the Review will vary according to the safety issues that need to be addressed; however in most cases, a limited scope review of compliance with the Safety Plan will be performed. During the review, a protocol will be assessed for compliance with the following Safety Monitoring Plan parameters:

Brookhaven Science Associates U.S. Department of Energy 6 PROTOCOL COMPLIANCE MONITORING n Safety Tests & Measures: i) Screening labs, safety tests, examinations, and observations ii) Subject eligibility criteria iii) Adherence to the treatment plan n Adverse events i) Occurrence of adverse & serious adverse events ii) Categorization of AE’s n Adverse event reporting i) To Sponsor, IRB, FDA, and NIH, & GCRC n Aggregate Analysis of Adverse Events i) Use of stopping rules ii) Reporting of aggregate analysis & DSMB reports

Brookhaven Science Associates U.S. Department of Energy 7 PROTOCOL COMPLIANCE MONITORING n Study monitoring i) Frequency of monitoring ii) Reporting mechanism of study staff to PI n Documents to be reviewed in a review may include any of the following: i) Case Report Forms (CRFs) or Study Worksheets ii) Medical Records, Laboratory Results, &/or Shadow Files iii) Signed Consent Forms iv) Drug Accountability Documentation v) Screening Logs vi) Protocol, Amendments, and IRB Correspondence vii) Regulatory Binders and Documentation including IRB record

Brookhaven Science Associates U.S. Department of Energy 8 PROTOCOL COMPLIANCE MONITORING n Following the review, the RSA will discuss with the investigative team any issues or concerns that are discovered during the review. This will allow time for resolution of issues prior to the writing of the report. n A written report by the RSA will be prepared upon completion of the review. This report will contain the findings of the review and recommendations from the Office of RSA. Recommendations could include corrective actions that are required for major and minor deviations that were noted in the review and the possible need for follow- up reviews. The RSA will report results of review directly to the Investigator, CRQAC and CORIHS with recommendations for further action as necessary.

Brookhaven Science Associates U.S. Department of Energy 9 PROTOCOL COMPLIANCE MONITORING n All review reports will be kept confidential. The reports will only be shared with the PI, the CRQAC and CORIHS. Copies of review reports will be kept in a locked file cabinet in the Office of RSA and access will be limited to RSA staff. n Reviews will focus on compliance with the safety-monitoring plan but may address other issues that are raised in regards to safety. There are two types of reviews: “for cause” reviews and random reviews. The CRQAC or CORIHS may request a “for cause” review of a protocol as a result of known or suspected problems in the conduct of human subject research.

Brookhaven Science Associates U.S. Department of Energy 10 PROTOCOL COMPLIANCE MONITORING n Other reasons for review may be: A protocol considered to be potential high risk due to the phase or nature of study (phase I, gene transfer, complex), number of adverse events occurring (or potential for AEs), subject population to be enrolled (vulnerable subjects) or the protocol has been determined by CORIHS to have significant risk Protocols with limited oversight or monitoring such as a Principal Investigator as the sole monitor for a study, no medical monitor or DSMB involved in monitoring the study or junior investigators or inexperienced team members who may benefit from a QA Review. Protocols for which faculty, staff, or research participants have raised concerns.